GH Research Announces Pricing of $117.5 Million Underwritten Offering
Rhea-AI Summary
GH Research (Nasdaq: GHRS) priced an underwritten offering of 6,527,779 ordinary shares at $18.00 per share for gross proceeds of approximately $117.5 million. The offering is expected to close on April 30, 2026, subject to customary closing conditions.
Joint book-runners are Stifel, Cantor and RBC Capital Markets; Lynx1 Capital initiated the offering with participation from Deep Track Capital and Foresite Capital. A registration statement was declared effective March 7, 2025.
Positive
- $117.5 million gross proceeds from the underwritten offering
- Sale of 6,527,779 ordinary shares priced at $18.00 per share
- Anchor participation from Lynx1, Deep Track, and Foresite signals institutional demand
Negative
- Offering proceeds subject to underwriting discounts, commissions and offering expenses
- Primary share issuance of 6,527,779 shares is dilutive to existing shareholders
- Closing is subject to customary conditions, so transaction is not final until close
News Market Reaction – GHRS
In the Apr 29 session, GHRS declined 3.48%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Offering Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 04 | Equity offering priced | Negative | -8.1% | Pricing of 10,000,000‑share public offering at $15 for $150M proceeds. |
| Feb 03 | Equity offering proposed | Negative | -9.3% | Announcement of proposed $150M public offering with underwriter option. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Past equity offerings for GHRS were followed by mid‑single‑digit to high‑single‑digit percentage declines, indicating a consistent negative reaction to dilution events.
Over the past year, GH Research has used follow‑on offerings to raise capital for its pipeline. On Feb 3–4, 2025, a proposed and then priced public offering targeting about $150 million in gross proceeds led to -9.31% and -8.06% one‑day moves. Today’s underwritten offering fits this pattern of funding clinical progress through share issuance, with prior offerings managed by the same banking group.
Key Terms
underwritten offering financial
registration statement regulatory
prospectus supplement regulatory
prospectus regulatory
prospectus regulation regulatory
qualified investors regulatory
financial promotion regulatory
relevant persons regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
DUBLIN, April 29, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today announced the pricing of an underwritten offering in the United States of 6,527,779 of its ordinary shares at an offering price of
The offering was initiated by Lynx1 Capital Management, with participation from Deep Track Capital and Foresite Capital.
Stifel, Cantor and RBC Capital Markets are acting as joint book-running managers for the offering. Canaccord Genuity and Citizens Capital Markets are acting as co-lead managers for the offering.
A registration statement relating to these securities was filed with the U.S. Securities and Exchange Commission (the "SEC") and declared effective on March 7, 2025. Copies of the registration statement can be accessed through the SEC's website free of charge at www.sec.gov. When available, copies of the final prospectus supplement and the accompanying prospectus related to the offering can be accessed through the SEC's website free of charge at www.sec.gov or obtained free of charge from any of the joint book-running managers for the offering: Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, California 94104, by telephone at (415) 364-2720, or by email at syndprospectus@stifel.com; Cantor Fitzgerald & Co., Attention: Capital Markets, 110 East 59th Street, 6th Floor, New York, New York 10022, or by email at prospectus@cantor.com; or RBC Capital Markets, LLC, Attention: Equity Capital Markets, 200 Vesey Street, New York, New York 10281, by telephone at 877-822-4089 or by email at equityprospectus@rbccm.com. For the avoidance of doubt, any such prospectus supplement or the accompanying prospectus will not constitute a “prospectus” for the purposes of the Irish Companies Act 2014 (as amended), the EU Prospectus Regulation (EU) 2017/1129 (as amended) (the “Prospectus Regulation”), the European Union (Prospectus) Regulations 2019 of Ireland (as amended) or the Central Bank (Investment Market Conduct) Rules 2019 of Ireland and will not have been reviewed by the Central Bank of Ireland, as competent authority, or any competent authority in any European Economic Area (the "EEA") member state or the United Kingdom.
This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.
In any member state of the EEA this announcement and any offering are only addressed to and directed at persons who are "qualified investors" ("Qualified Investors") within the meaning of the Prospectus Regulation. In the United Kingdom, this announcement and any offering are only addressed to and directed at Qualified Investors (i) who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "Order"), or (ii) who fall within Article 49(2)(a) to (d) of the Order, and (iii) to whom it may otherwise lawfully be communicated (all such persons being referred to as "relevant persons").
This announcement must not be acted on or relied on (i) in the United Kingdom, by persons who are not relevant persons, and (ii) in any member state of the EEA, by persons who are not Qualified Investors. Any investment or investment activity to which this announcement relates is available only to and will only be engaged with (i) in the United Kingdom, relevant persons, and (ii) in any member state of the EEA, Qualified Investors.
About GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression. GH Research PLC's initial focus is on developing its novel and proprietary mebufotenin therapies for the treatment of patients with treatment-resistant depression (TRD).
Forward-Looking Statements
This press release contains certain forward-looking statements, including statements with regard to GH Research PLC’s expectations regarding the completion of the proposed securities offering. Words such as “anticipates,” “believes,” “expects,” “intends,” “projects,” and “future” or similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to the inherent uncertainties in predicting future results and conditions and no assurance can be given that the proposed securities offering discussed above will be consummated on the terms described or at all. Completion of the proposed offering and the terms thereof are subject to numerous factors, many of which are beyond the control of GH Research PLC, including, without limitation, market conditions, failure of customary closing conditions and the risk factors and other matters set forth in GH Research PLC’s filings with the SEC. GH Research PLC undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.
Investor Relations:
Julie Ryan
GH Research PLC
investors@ghres.com
